SCHEMBL24912696

SCHEMBL24912696

Cc1cnc(C(=O)O)c(C(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 3/20 0.40
FABP3 P05413 1/20 0.40
FABP4 P15090 1/20 0.40
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
TPMT P51580 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33
GABRA4 P48169 1/20 0.33
GABRE P78334 1/20 0.33
GABRA6 Q16445 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16011538 0.80 GABRA1 (0.42) HCAR2FABP3FABP4GABRA1GABRB1
SCHEMBL7190906 0.76 HCAR2 (0.45) HCAR2KDM4EALDH1A1MAPTTPMT
SCHEMBL19913411 0.76 AGBL2 (0.45) KDM4EALDH1A1MAPTLMNA
SCHEMBL30968742 0.75 GABRP (0.44) HCAR2KDM4EALDH1A1MAPTTPMT
SCHEMBL1819716 0.75 GABRP (0.44) HCAR2KDM4EALDH1A1MAPTTPMT
SCHEMBL9508588 0.75 HCAR2 (0.44) HCAR2KDM4EALDH1A1MAPTTPMT
SCHEMBL14212262 0.75 HCAR2 (0.48) HCAR2KDM4EALDH1A1MAPTTPMT
SCHEMBL15431710 0.73 HCAR2 (0.42) HCAR2KDM4EALDH1A1MAPTTPMT
SCHEMBL12629426 0.73 GABRP (0.43) HCAR2KDM4EALDH1A1MAPTTPMT
Bromide SCHEMBL20840237 0.73 HCAR2 (0.47) HCAR2KDM4EALDH1A1MAPTTPMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-16 US disclosed
US-20230017140-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PIK3CA, PIK3R4, PIK3R5 HCAR2 2247/4885FABP3 2873/4885FABP4 4496/4885
US-20230017140-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 HCAR2 2247/4885FABP3 2873/4885FABP4 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.